The first clinically-focused systematic review of cannabis for psychiatric disorders found tentative support for CBD in social anxiety and mixed positive evidence for adjunctive CBD in schizophrenia, with high-THC formulations showing no benefit for depression.
Psychiatrists considering cannabis prescriptions, clinical psychologists, and patients exploring cannabinoid options for mental health.
CBD: promising for social anxiety; high-THC: no benefit for depression
What the researchers found
CBD showed tentative support for reducing social anxiety. Mixed but mainly positive evidence supported adjunctive CBD in schizophrenia. Case studies suggested benefits for sleep and PTSD. High-THC therapeutics showed no benefit for depression. One study suggested oral cannabinoid/terpene combinations may help ADHD. Key prescriptive caution: avoid high-THC in youth, anxiety-prone, or psychosis-prone individuals; titrate gradually; monitor cardiovascular and respiratory function.
Why it matters
This is described as the first clinically-focused systematic review covering all major psychiatric disorders. It bridges the gap between research evidence and clinical practice, providing specific prescribing guidance alongside the evidence.
The numbers in context
CBD: tentative support for social anxiety; mixed positive for schizophrenia adjunct; case-study level for sleep and PTSD; high-THC: no depression benefit; one study suggests cannabinoid/terpene for ADHD.
How the study worked
Systematic review of all case studies and clinical trials involving medicinal cannabis or plant-derived isolates for major psychiatric disorders (2019), including clinical prescription considerations and pharmacogenomics.
What this study cannot tell us
Evidence described as "embryonic" by authors; most psychiatric disorder evidence at case-study level; systematic review encompasses heterogeneous study types; pharmaceutical CBD and whole-plant products may differ; limited long-term safety data.
How to read the evidence
Moderate: comprehensive systematic review with clinical focus, but underlying evidence is mostly embryonic.
When this study was published
Published 2020.
The bigger picture
The pattern is clear: CBD shows promise while high-THC formulations show risk. This has direct implications for how medicinal cannabis should be prescribed for psychiatric conditions: CBD-dominant formulations with careful THC avoidance in vulnerable populations.
Questions still open
- Is CBD alone sufficient for psychiatric benefits, or do trace cannabinoids contribute? What dose and duration of CBD are optimal for social anxiety?
Common questions
Can medical cannabis treat psychiatric disorders?
Should I use CBD or THC for mental health?
Read the original research
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
BMC psychiatry, 20(1), 24
Citation
Sarris, Jerome; Sinclair, Justin; Karamacoska, Diana; Davidson, Maggie; Firth, Joseph. (2020). Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.. BMC psychiatry, 20(1), 24. https://doi.org/10.1186/s12888-019-2409-8
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk